Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACXP NYSE:CANF NASDAQ:DWTX NASDAQ:XFOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACXPAcurx Pharmaceuticals$5.11+5.1%$8.40$3.80▼$47.80$7.70M-1.2762,381 shs99,836 shsCANFCan-Fite BioPharma$0.66-1.6%$0.94$0.63▼$3.12$2.34M1.02211,613 shs78,807 shsDWTXDogwood Therapeutics$4.93+0.2%$4.82$1.62▼$29.28$9.40M1.814,631 shs11,608 shsXFORX4 Pharmaceuticals$2.85-9.2%$2.08$1.35▼$26.83$18.18M0.610.67 million shs1.83 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACXPAcurx Pharmaceuticals+2.97%+4.52%-43.96%-37.21%-87.21%CANFCan-Fite BioPharma-1.79%-2.73%-35.31%-35.62%-72.74%DWTXDogwood Therapeutics+2.69%+0.80%+4.87%-7.35%+492,899,900.00%XFORX4 Pharmaceuticals+7.17%+115.07%+113.61%+7.53%-82.94%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACXPAcurx Pharmaceuticals3.0273 of 5 stars3.55.00.00.02.71.70.0CANFCan-Fite BioPharma1.9815 of 5 stars3.52.00.00.01.10.01.3DWTXDogwood Therapeutics1.6187 of 5 stars3.50.00.00.01.60.00.6XFORX4 Pharmaceuticals4.3624 of 5 stars3.52.00.04.62.43.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACXPAcurx Pharmaceuticals 3.00Buy$31.00506.65% UpsideCANFCan-Fite BioPharma 3.00Buy$14.002,018.00% UpsideDWTXDogwood Therapeutics 3.00Buy$10.00102.84% UpsideXFORX4 Pharmaceuticals 3.00Buy$71.172,397.08% UpsideCurrent Analyst Ratings BreakdownLatest CANF, ACXP, DWTX, and XFOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/13/2025XFORX4 PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$7.00 ➝ $3.508/12/2025ACXPAcurx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$31.007/29/2025CANFCan-Fite BioPharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/15/2025ACXPAcurx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$160.00(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACXPAcurx PharmaceuticalsN/AN/AN/AN/A$2.25 per shareN/ACANFCan-Fite BioPharma$674K3.47N/AN/A$1.76 per share0.38DWTXDogwood TherapeuticsN/AN/AN/AN/A($9.48) per shareN/AXFORX4 Pharmaceuticals$2.56M6.45N/AN/A$0.69 per share4.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACXPAcurx Pharmaceuticals-$14.10M-$10.69N/AN/AN/AN/A-436.83%-192.25%N/ACANFCan-Fite BioPharma-$7.63M-$1.79N/AN/AN/AN/AN/AN/AN/ADWTXDogwood Therapeutics-$12.35M-$18.78N/AN/AN/AN/AN/A-27.41%N/AXFORX4 Pharmaceuticals-$37.45M-$14.84N/AN/AN/A-311.15%-375.31%-72.87%N/ALatest CANF, ACXP, DWTX, and XFOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025DWTXDogwood Therapeutics-$1.26-$1.99-$0.73-$1.99N/AN/A8/11/2025Q2 2025ACXPAcurx Pharmaceuticals-$2.00-$1.89+$0.11-$1.89N/AN/A8/8/2025Q2 2025XFORX4 Pharmaceuticals-$4.53-$3.47+$1.06-$3.47$1.62 million$1.97 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACXPAcurx PharmaceuticalsN/AN/AN/AN/AN/ACANFCan-Fite BioPharmaN/AN/AN/AN/AN/ADWTXDogwood TherapeuticsN/AN/AN/AN/AN/AXFORX4 PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACXPAcurx PharmaceuticalsN/A2.381.93CANFCan-Fite BioPharmaN/A2.93N/ADWTXDogwood TherapeuticsN/A7.807.43XFORX4 Pharmaceuticals19.103.193.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACXPAcurx Pharmaceuticals11.53%CANFCan-Fite BioPharma21.00%DWTXDogwood Therapeutics9.05%XFORX4 Pharmaceuticals72.03%Insider OwnershipCompanyInsider OwnershipACXPAcurx Pharmaceuticals20.30%CANFCan-Fite BioPharma0.80%DWTXDogwood Therapeutics3.90%XFORX4 Pharmaceuticals2.37%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACXPAcurx Pharmaceuticals31.58 million1.26 millionOptionableCANFCan-Fite BioPharma83.54 millionN/ANot OptionableDWTXDogwood Therapeutics51.91 million1.84 millionN/AXFORX4 Pharmaceuticals805.79 million5.65 millionOptionableCANF, ACXP, DWTX, and XFOR HeadlinesRecent News About These CompaniesX4 Pharmaceuticals Grants Inducement Equity Awards to New Executive OfficersAugust 15 at 4:22 PM | quiverquant.comQX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 15 at 4:05 PM | globenewswire.comX4 Pharmaceuticals Closes $85M Private Placement DealAugust 14 at 1:40 PM | theglobeandmail.comX4 Pharmaceuticals price target lowered to $3.50 from $7 at H.C. WainwrightAugust 13 at 5:48 PM | msn.comX4 Pharmaceuticals Stock Rises On Closing Of Upsized Offering, But Brokerage Lowers Price TargetAugust 13 at 5:48 PM | msn.comX4 Pharmaceuticals Announces Closing of Upsized $85 Million Private PlacementAugust 13 at 7:00 AM | globenewswire.comX4 Pharmaceuticals announces $60M financing, management changesAugust 12 at 5:08 PM | msn.comX4 Pharmaceuticals Announces $60M Equity FinancingAugust 12 at 5:08 PM | msn.comX4 Pharmaceuticals secures $60M PIPE financingAugust 12 at 5:08 PM | msn.comX4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board LeadershipAugust 12 at 7:00 AM | globenewswire.comX4 Pharmaceuticals, Inc. (XFOR) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comX4 Pharmaceuticals Inc News (XFOR) - Investing.comJuly 2, 2025 | investing.comXFOR X4 Pharmaceuticals, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comX4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)June 16, 2025 | globenewswire.comX4 Pharmaceuticals Gets Fast Track Regulatory Designation for Neutropenia DrugJune 10, 2025 | marketwatch.comX4 Pharmaceuticals gains on fast-track designation for mavorixafor for treatment of chronic neutropeniaJune 10, 2025 | msn.comX4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDAJune 10, 2025 | globenewswire.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2, 2025 | globenewswire.comX4 Pharmaceuticals Reports Positive Phase 2 Trial Results for Mavorixafor in Chronic Neutropenia, Accepted for Presentation at EHA CongressMay 16, 2025 | nasdaq.comX4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA CongressMay 14, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCANF, ACXP, DWTX, and XFOR Company DescriptionsAcurx Pharmaceuticals NASDAQ:ACXP$5.11 +0.25 (+5.14%) Closing price 04:00 PM EasternExtended Trading$5.04 -0.08 (-1.47%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.Can-Fite BioPharma NYSE:CANF$0.66 -0.01 (-1.64%) Closing price 03:47 PM EasternExtended Trading$0.67 +0.01 (+0.76%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.Dogwood Therapeutics NASDAQ:DWTX$4.93 +0.01 (+0.20%) Closing price 03:54 PM EasternExtended Trading$4.95 +0.02 (+0.49%) As of 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.X4 Pharmaceuticals NASDAQ:XFOR$2.85 -0.29 (-9.24%) Closing price 04:00 PM EasternExtended Trading$2.82 -0.03 (-0.91%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNH Deere’s Sell-Off Could Be a Long-Term Buying Chance 3 Restaurant Stocks That Will Outperform in Q3 and Q4 Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore Arista Networks: Cashing In as the Tollbooth for AI Traffic Green Dot's 30% Rally: Turnaround Takes Off on Explosive Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.